"The NRG Oncology Podcast" New Episode Sept 16! | |
|
During our next episode of The NRG Oncology Podcast, we will be talking with Dr. Robert Mannel, NRG Group Chair, about Gynecologic Oncology, NRG trials & committees & more! Tune in monthly for new episodes on either Spotify, Apple Podcasts, or YouTube. Be sure to follow or subscribe to see more episodes as they are posted!
Listen on Spotify/Apple Podcasts/YouTube
| |
|
Annual Call for Committee Membership Applications
Are you interested in serving on an NRG Oncology committee? NRG Oncology depends on its members to advance its mission. Our members help drive our research, develop protocols, contribute to our science, and so much more. If you are interested in serving on an NRG Oncology research committee, or if you are a member who had previously served on a committee and would like to re-engage please consider applying by following the instructions in the 2024 NRG ONCOLOGY GENERAL AND CORE COMMITTEES APPLICATION FORM and submitting a complete application.
All applications must be submitted by midnight ET October 9, 2024.
Current committee members do not need to reapply.
The next call for applications for core and general committees will occur in the Fall 2025.
| |
|
My Hereditary Cancer Journey: Looking Back, Look Forward
Article by Diane Rose, an NRG Oncology Patient Advocate
| |
Sixteen years ago, when I started my hereditary cancer journey, I vividly remember thinking that by the time my youngest child, my daughter, reached the age where she would need to consider genetic counseling and testing, there would be many advances in genetics, screening tools, and options for preventing breast and ovarian cancer. While many advances have been made, we are still, in many respects, at the same place for screening tools and prevention options as my daughter considers genetic testing while finishing her undergraduate studies. | |
|
NRG Member Demographics Data Collection Initiative | |
|
We are excited to introduce the NRG Member Demographics Data Collection Initiative that will allow us to create a comprehensive member database, enabling us to better understand and serve our members. Your information will be kept secure and confidential, ensuring that your privacy is always protected. All members are encouraged to complete the form or indicate that they wish to opt out of this data collection initiative. This is a new form and not part of the anonymous climate survey that we sent out last year.
Please be prepared with your CTEP ID. If you need to obtain your CTEP ID, please visit www.CTEPcore.nci.nih.gov/iam or login to www.CTSU.org.
Scan the QR code below or click this link to access the form.
Questions? Read more here
| |
Protocol Support Committee (PSC) Column | |
Written by Belinda Buehl, Regulatory Coordinator, University of Wisconsin Hospital and Clinics, Department of Human Oncology -Radiation Oncology | |
The DTL or Delegation of Tasks Log application within the CTSU is utilized to document the delegation of tasks for the study team. The site-level Clinical Investigator or CI delegates the tasks to the appropriately trained team members at the site for individual studies. Delegated tasks can vary per protocol. Signed/approved DTLs are required to obtain site registration approval. Without a signed DTL, sites cannot enroll subjects via the Oncology Patient Enrollment Network (OPEN). | |
NRG Study News & New Protocols Under Development | |
|
Comparing Stereotactic Radiosurgery to Fractionated Stereotactic Radiosurgery for Patients with Cancer that has Spread to the Brain (NRG-BN013)
NRG-BN013: Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases
The NRG-BN013 phase III clinical trial was recently activated as a part of the NRG Oncology brain tumor portfolio. NRG-BN013 will compare two schedules of stereotactic radiosurgery (SRS) for patients with intact (i.e., unresected) brain metastases. The primary objective of the study is to determine if fractionated SRS (FSRS) with three treatments of radiotherapy over the course of a week improves the time to local failure over the usual treatment of one radiotherapy treatment in a single day for this population.
| |
PI Interview: The "COMMIT" Study of Immunotherapy for dMMR Metastatic Colorectal Cancer (NRG-GI004/SWOG S1610)
NRG-GI004/S1610: Colorectal Cancer Metastatic dMMR/MSI-H Immuno-therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-high (MSI-H) Metastatic Colorectal Cancer
NRG Oncology interviewed Dr. Caio Max Sao Pedro Rocha Lima, the Principal Investigator of the COMMIT Study at Wake Forest University Baptist Health, to provide insights, on this important clinical trial to the accruing sites.
| |
New Protocols Under Development | |
Video Interviews
NRG-GU013 Video Interview with Dr. Hoffman
Currently enrolling patients, NRG-GU013 is a phase III trial testing shorter duration radiation therapy vs. the usual radiation therapy in patients with high-risk prostate cancer. Watch as Dr. Karen Hoffman, principal investigator for NRG-GU013, provides an overview about the “High Five” clinical trial.
| |
|
NRG-GY026 Video Interview with Dr. Erickson
The NRG-GY026 study is evaluating the efficacy of trastuzumab and hyaluronidase-oysk and pertuzumab, trastuzumab, and hyaluronidase-zzxf in combination with paclitaxel/carboplatin in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Watch our video interview with Dr. Britt Erickson as she discusses this clinical trial that is currently enrolling patients.
| |
|
NRG Oncology GYN Cancer Committee is Requesting Proposals for Clinical Trials in Advance of the October 11th GYN Virtual Interim Meetings
Contact Kia Neff at neffk@nrgoncology.org prior to developing proposal. She will put you in contact with a committee member who can guide you so as not to duplicate efforts and inform where a proposal has previously been disapproved.
Proposals are to be submitted on the CTEP LOI submission form (phase I trials, small phase I/II trials, small phase II trials) or the CTEP concept submission form. Current versions of CTEP LOI submission form and concept submission form can be found at: https://ctep.cancer.gov/protocolDevelopment/lois_concepts.htm.
Submit completed proposals to GYNconcepts@nrgoncology.org by September 26, 2024.
| |
|
NCORP Updates
NCORP Pilot Project Awardees
| |
NRG Oncology NCORP solicited pilot projects earlier this year and is pleased to announce that two proposals were selected. The awards fund projects that have high potential to lead to competitive NRG NCORP concepts. | |
FORTE enrolled its 1800th participant on August 1, 2024, less than a month after enrolling the 1700th participant!
| |
FORTE Coordinator Session - August 7, 2024 | |
The FORTE Coordinator Session was held online on August 7, where presenters from various enrolling sites discussed best practices for FORTE. The recording of the session is available on the FORTE YouTube channel for your review at any time. | |
|
PAC Member presents at NCI 2024 Speaker Series
Wenora Johnson recently presented about her journey, perspective, and experience as an oncology patient advocate and lived-experience expert, during the NCI Center for Cancer Research’s Office of Healthcare Delivery and Equity Research, three-part webinar series “The Role of Patient Advocates in Advancing Inclusive Clinical Research” on August 19. Read more.
| |
#NRG2024 Summer Meeting in Denver | | | | |
